John Videen, MD
Nephrology · Chula Vista, CANPI 1043318199
Payments from drug & device makers
Across 280 payments — averaging $103.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$8K
- Fresenius USA Marketing, Inc.$5K
- Calliditas Therapeutics US Inc.$3K
- Grifols Biologicals LLC$2K
- AstraZeneca$2K
- Amgen$2K
- plus $7K from 31 others
What the payments were for
- Consulting fees$8,33029%
- Speaking & faculty fees$4,70016%
- Travel & lodging$4,89617%
- Food & beverage$10,86837%
- Education$2731%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 25 | $8,257 |
| Fresenius USA Marketing, Inc. | 22 | $5,155 |
| Calliditas Therapeutics US Inc. | 8 | $2,512 |
| Grifols Biologicals LLC | 5 | $2,490 |
| AstraZeneca(2 entities) | 47 | $2,251 |
| Amgen(2 entities) | 45 | $1,865 |
| Baxter Healthcare | 1 | $1,700 |
| Aurinia Pharma U.S., Inc. | 9 | $463 |
| Nxstage Medical, Inc. | 8 | $448 |
| Mallinckrodt Hospital Products Inc. | 5 | $431 |
| Vifor Pharma, Inc. | 14 | $427 |
| Otsuka America Pharmaceutical, Inc. | 12 | $343 |
| Dexcom, Inc. | 6 | $259 |
| Akebia Therapeutics Inc | 7 | $255 |
| Abbott | 3 | $221 |
| Boehringer Ingelheim | 7 | $212 |
| OPKO Pharmaceuticals, LLC | 6 | $200 |
| Travere Therapeutics, Inc. | 6 | $163 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $158 |
| Apellis Pharmaceuticals, Inc. | 1 | $145 |
| Grifols Therapeutics LLC | 3 | $143 |
| GSK | 7 | $140 |
| Novo Nordisk | 7 | $127 |
| Lilly USA, LLC | 5 | $121 |
| Boston Scientific | 1 | $121 |
| Novartis | 3 | $99 |
| Daiichi Sankyo Inc. | 5 | $74 |
| Ardelyx, Inc. | 1 | $67 |
| Kyowa Kirin, Inc. | 1 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $48 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Merck | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Veloxis Pharmaceuticals, Inc. | 1 | $15 |
| Biomerieux Inc | 1 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$7,774
- Velphoro$4,767
- TARPEYO$2,370
- Albutein$2,343
- Renal - Acute$1,700
- Parsabiv$476
- TERLIVAZ$395
- LUPKYNIS$353
- KRYSTEXXA$254
- ULTOMIRIS$242
- Vafseo$156
- DEXCOM G7 GSS (161)$151
- CardioMEMS HF System$148
- FARXIGA$137
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$121
- JARDIANCE$119
- Tavneos$117
- NXSTAGE SYSTEM ONE$114
How this compares
$29,067 in reported general payments places this provider in the 80th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 141 | $163,477 |
| VelphoroSucroferric Oxyhydroxide | 42 | $158,997 |
| JardianceEmpagliflozin | 82 | $98,971 |
| OzempicSemaglutide | 62 | $77,215 |
| AuryxiaFerric Citrate | 22 | $51,427 |
| TrulicityDulaglutide | 30 | $47,967 |
| KerendiaFinerenone | 27 | $36,856 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $35,290 |
| Sevelamer Carbonate | 73 | $19,291 |
| TradjentaLinagliptin | 16 | $18,580 |
| DapagliflozinDapagliflozin Propanediol | 30 | $16,774 |
| ProcritEpoetin Alfa | 15 | $13,913 |
| JanuviaSitagliptin Phosphate | 15 | $12,363 |
| Cinacalcet Hcl | 15 | $4,225 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 24 | $3,571 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $2,251 | $163,477141 claims |
| Fresenius USA Marketing, Inc.Velphoro | $5,155 | $158,99742 claims |
| Boehringer IngelheimJardiance, Tradjenta | $212 | $117,55198 claims |
| Novo NordiskOzempic | $127 | $77,21562 claims |
| Akebia Therapeutics IncAuryxia | $255 | $51,42722 claims |
| Lilly USA, LLCTrulicity | $121 | $47,96730 claims |
| BayerKerendia | $8,257 | $36,85627 claims |
| MerckJanuvia | $18 | $12,36315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,341 nephrology providers in California.
Other nephrology in Chula Vista
- Jill MeyerChula Vista$1.8M
- Diogo BeloChula Vista$1.1M
- Adam HoreishChula Vista$1M
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.